Granules India Ltd vs Kabra Drugs Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 05, 2026

Key Highlights

The Latest Trading Price of Granules India Ltd is ₹ 711.85 as of 05 May 15:30 . The P/E Ratio of Granules India Ltd changed from 13.7 on March 2021 to 23.5 on March 2025 . This represents a CAGR of 11.40% over 5 yearsThe P/E Ratio of Kabra Drugs Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 years The Market Cap of Granules India Ltd changed from ₹ 7511 crore on March 2021 to ₹ 11814 crore on March 2025 . This represents a CAGR of 9.48% over 5 yearsThe Market Cap of Kabra Drugs Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 years The revenue of Granules India Ltd for the Mar '26 is ₹ 1495 crore as compare to the Dec '25 revenue of ₹ 1384 crore. This represent the growth of 8.02% The revenue of Kabra Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Granules India Ltd for the Mar '26 is ₹ 376.79 crore as compare to the Dec '25 ebitda of ₹ 304.46 crore. This represent the growth of 23.76% The ebitda of Kabra Drugs Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The net profit of Granules India Ltd changed from ₹ 134.65 crore to ₹ 201.57 crore over 8 quarters. This represents a CAGR of 22.35% The net profit of Kabra Drugs Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The Dividend Payout of Granules India Ltd changed from 6.72 % on March 2021 to 11.39 % on March 2025 . This represents a CAGR of 11.13% over 5 yearsThe Dividend Payout of Kabra Drugs Ltd changed from 0 % on March 2021 to 0 % on March 2025 . This represents a CAGR of 0.0% over 5 years .

About Granules India Ltd

Granules India Limited is a large-scale vertically integrated company founded in March, 1991 manufacturing Active Pharmaceutical Ingredient (API), Pharmaceutical Formulation Intermediate (PFI) and Finished Dosage (FD).
With a strong presence across all three vertical, the company has created a leadership position in the off-patent drugs segment along with ensuring a strong presence in first line of defense' products such as Paracetamol, Ibuprofen, Metformin and Guaifenesin.
Granules India is the preferred supplier for some of the world's leading pharma branded and generics companies. Granules Life Sciences Private Limited, based in Hyderabad, Telangana, is a wholly owned subsidiary of Granules India.
It significantly enhances the Company's finished dosage manufacturing capabilities, contributing an additional 10 billion dosage units annually.

About Kabra Drugs Ltd

Kabra Drugs Ltd was incorporated as a Limited Company on August 22, 1989.
The Company has set up a Unit at Indore for manufacturing of Ether derivatives which includes Diethyl Ether (Anesthesia), Solvent Ether, Ethyl Chloride Spray (General Anesthesia) and Surgical.
The commercial production commenced in 1991.
Kabra Drugs Limited is the only manufacturer of Ether derivatives in the State of M.P. tHE Company is presently engaged in the business of Permaculture manufacturing and trading in pharma related products. The latest addition to the product line is the range of disinfectants which includes hand wash gel, hand sanitizer and antimicrobial gel.
In India there are very few manufacturers who are manufacturing the said products.

FAQs for the comparison of Granules India Ltd and Kabra Drugs Ltd

Which company has a larger market capitalization, Granules India Ltd or Kabra Drugs Ltd?

Market cap of Granules India Ltd is 17,639 Cr while Market cap of Kabra Drugs Ltd is 58 Cr

What are the key factors driving the stock performance of Granules India Ltd and Kabra Drugs Ltd?

The stock performance of Granules India Ltd and Kabra Drugs Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Granules India Ltd and Kabra Drugs Ltd?

As of May 6, 2026, the Granules India Ltd stock price is INR ₹711.85. On the other hand, Kabra Drugs Ltd stock price is INR ₹24.51.

How do dividend payouts of Granules India Ltd and Kabra Drugs Ltd compare?

To compare the dividend payouts of Granules India Ltd and Kabra Drugs Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.